Cargando…

Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals

Direct antiviral agents (DAAs) have excellent efficacy against chronic hepatitis C virus (HCV) infection. Despite this strength, recent studies raised concerns about an unexpected hepatocellular carcinoma (HCC) occurrence rate after DAA therapy. In this exploratory case-control study, we evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pascut, Devis, Cavalletto, Luisa, Pratama, Muhammad Yogi, Bresolin, Silvia, Trentin, Luca, Basso, Giuseppe, Bedogni, Giorgio, Tiribelli, Claudio, Chemello, Liliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895878/ https://www.ncbi.nlm.nih.gov/pubmed/31717959 http://dx.doi.org/10.3390/cancers11111773

Ejemplares similares

Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma
por: Pratama, Muhammad Yogi, et al.
Publicado: (2020)

Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals
por: Cabral, Loraine Kay D., et al.
Publicado: (2022)

Circulatory miRNA as a Biomarker for Therapy Response and Disease-Free Survival in Hepatocellular Carcinoma
por: Pratama, Muhammad Yogi, et al.
Publicado: (2020)

Weighted miRNA co-expression networks analysis identifies circulating miRNA predicting overall survival in hepatocellular carcinoma patients
por: Pascut, Devis, et al.
Publicado: (2020)

HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development
por: Pascut, Devis, et al.
Publicado: (2021)

The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence
por: Cavalletto, Luisa, et al.
Publicado: (2023)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
por: Pascut, Devis, et al.
Publicado: (2020)

The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and Their Clinical Implications
por: Pascut, Devis, et al.
Publicado: (2020)

Silencing efficacy prediction: a retrospective study on target mRNA features
por: Pascut, Devis, et al.
Publicado: (2015)

The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer
por: Masadah, Rina, et al.
Publicado: (2021)

Circulating microRNA Associated to Different Stages of Liver Steatosis in Prader–Willi Syndrome and Non-Syndromic Obesity
por: Pratama, Muhammad Yogi, et al.
Publicado: (2020)

Differences in circulating microRNA signature in Prader–Willi syndrome and non-syndromic obesity
por: Pascut, Devis, et al.
Publicado: (2018)

Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma
por: Sukowati, Caecilia H. C., et al.
Publicado: (2021)

Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma
por: Ladju, Rusdina Bte, et al.
Publicado: (2017)

Correction: Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma
por: Ladju, Rusdina Bte, et al.
Publicado: (2018)

Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma
por: Sukowati, Caecilia HC, et al.
Publicado: (2012)

MiR-3201 as a Prognostic Blood Biomarker for Curative Treatments in Hepatocellular Carcinoma
por: Grisetti, Luca, et al.
Publicado: (2022)

Prognostic Value of Liver and Spleen Stiffness in Patients with Fontan Associated Liver Disease (FALD): A Case Series with Histopathologic Comparison
por: Padalino, Massimo A., et al.
Publicado: (2021)

Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma
por: Sukowati, Caecilia H. C., et al.
Publicado: (2018)

Repeated double cross-validation applied to the PCA-LDA classification of SERS spectra: a case study with serum samples from hepatocellular carcinoma patients
por: Gurian, Elisa, et al.
Publicado: (2020)

Role of Transient Elastography to Stage Fontan-Associated Liver Disease (FALD) in Adults with Single Ventricle Congenital Heart Disease Correction
por: Chemello, Liliana, et al.
Publicado: (2021)

Clinical Significance of Apurinic/Apyrimidinic Endodeoxyribonuclease 1 and MicroRNA Axis in Hepatocellular Carcinoma
por: Mangiapane, Giovanna, et al.
Publicado: (2023)

A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients
por: Pascut, Devis, et al.
Publicado: (2019)

Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma
por: Pascut, Devis, et al.
Publicado: (2019)

Bilirubin-Induced Transcriptomic Imprinting in Neonatal Hyperbilirubinemia
por: Llido, John Paul, et al.
Publicado: (2023)

A simple index of lipid overaccumulation is a good marker of liver steatosis
por: Bedogni, Giorgio, et al.
Publicado: (2010)

Liver Angiopoietin‐2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct‐Acting Antivirals
por: Faillaci, Francesca, et al.
Publicado: (2018)

Proteome profiling identifies circulating biomarkers associated with hepatic steatosis in subjects with Prader-Willi syndrome
por: Pascut, Devis, et al.
Publicado: (2023)

The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease
por: Nobili, Valerio, et al.
Publicado: (2009)

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population
por: Bedogni, Giorgio, et al.
Publicado: (2006)

Association of Serum Bilirubin Level with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study of 1672 Obese Children
por: Bellarosa, Cristina, et al.
Publicado: (2021)

Bilirubin: A Promising Therapy for Parkinson’s Disease
por: Jayanti, Sri, et al.
Publicado: (2021)

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response
por: Itami-Matsumoto, Saori, et al.
Publicado: (2019)

Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology
por: Chavez-Tapia, Norberto C, et al.
Publicado: (2009)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
por: Hassany, Sahar M, et al.
Publicado: (2020)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Antiviral Effects and Underlying Mechanisms of Probiotics as Promising Antivirals
por: Wang, Yanjin, et al.
Publicado: (2022)

Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort
por: Quaranta, Maria Giovanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3t38eogt8ks29d7tng2n87dj9p